LADENBURG THALM/SH SH Boosts TG Therapeutics (NASDAQ:TGTX) Price Target to $40.00

TG Therapeutics (NASDAQ:TGTX) had its target price lifted by LADENBURG THALM/SH SH from $39.00 to $40.00 in a report released on Thursday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. HC Wainwright restated a buy rating and set a $45.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. B. Riley upped their target price on TG Therapeutics from $24.00 to $29.00 and gave the stock a buy rating in a research note on Monday, February 5th. JPMorgan Chase & Co. reiterated an overweight rating and set a $25.00 price target on shares of TG Therapeutics in a research report on Thursday, April 18th. StockNews.com lowered TG Therapeutics from a buy rating to a hold rating in a research report on Saturday, February 24th. Finally, The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a neutral rating in a research note on Thursday, February 29th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, TG Therapeutics currently has a consensus rating of Moderate Buy and an average price target of $29.83.

TG Therapeutics Trading Down 1.4 %

TG Therapeutics stock opened at $16.19 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The stock has a market cap of $2.50 billion, a PE ratio of 70.39 and a beta of 2.33. The stock has a 50-day moving average of $15.25 and a two-hundred day moving average of $14.46. TG Therapeutics has a one year low of $6.46 and a one year high of $35.67.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $63.47 million during the quarter, compared to analysts’ expectations of $54.60 million. TG Therapeutics had a return on equity of 33.79% and a net margin of 14.24%. The company’s quarterly revenue was up 713.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.28) EPS. On average, research analysts anticipate that TG Therapeutics will post -0.11 EPS for the current fiscal year.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total transaction of $351,340.00. Following the completion of the sale, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a document filed with the SEC, which is available through this link. 9.20% of the stock is currently owned by corporate insiders.

Institutional Trading of TG Therapeutics

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in TG Therapeutics by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock worth $233,500,000 after purchasing an additional 199,770 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of TG Therapeutics by 1.4% during the 4th quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock worth $53,627,000 after purchasing an additional 43,290 shares during the last quarter. Opaleye Management Inc. grew its position in shares of TG Therapeutics by 17.2% in the fourth quarter. Opaleye Management Inc. now owns 2,215,000 shares of the biopharmaceutical company’s stock valued at $37,832,000 after purchasing an additional 325,000 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in shares of TG Therapeutics by 164.5% in the third quarter. Schonfeld Strategic Advisors LLC now owns 1,367,400 shares of the biopharmaceutical company’s stock valued at $11,431,000 after purchasing an additional 850,507 shares during the last quarter. Finally, 683 Capital Management LLC purchased a new stake in TG Therapeutics in the 3rd quarter valued at $11,286,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.